Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Xizhong Cui
1, Leisha D. Nolen
1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. Eichacker
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)
Main Article
Figure 3
Figure 3. Individual LF levels (nanograms per milliliter) in 12 anthrax patients receiving AIG-IV from 10 h before until 50 h after treatment administration, Scotland, UK, 2009–2010. AIG-IV, anthrax immune hlobulin intravenous; LF, lethal factor.
Main Article
Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.